Is Memphasys (ASX:MEM) Using Too Much Debt?
Jun 19
Australian (ASX) Clinical Research and Equipment Industry Analysis
UpdatedJul 26, 2024
DataAggregated Company Financials
Companies8
- 7D-3.4%
- 3M8.7%
- 1Y-6.3%
- YTDn/a
Over the last 7 days, the Clinical Research and Equipment industry has dropped 1.3%, driven by EZZ Life Science Holdings declining 12%. In contrast, Memphasys has gained 13%. Overall the industry is down 5.8% in 12 months. As for the next few years, earnings are expected to grow by 67% per annum.
Industry Valuation and Performance
Has the Australian Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 26 Jul 2024 | AU$634.2m | AU$246.1m | -AU$49,506,434.00 | 28.4x | -12.8x | 2.6x |
| Sun, 23 Jun 2024 | AU$574.4m | AU$246.1m | -AU$49,506,434.00 | 26.2x | -11.6x | 2.3x |
| Tue, 21 May 2024 | AU$558.2m | AU$246.1m | -AU$49,506,434.00 | 20.1x | -11.3x | 2.3x |
| Thu, 18 Apr 2024 | AU$573.7m | AU$246.1m | -AU$49,506,434.00 | 16.2x | -11.6x | 2.3x |
| Sat, 16 Mar 2024 | AU$547.3m | AU$246.1m | -AU$49,506,434.00 | 13x | -11.1x | 2.2x |
| Mon, 12 Feb 2024 | AU$490.4m | AU$248.2m | -AU$39,797,313.00 | 22.5x | -12.3x | 2x |
| Wed, 10 Jan 2024 | AU$472.1m | AU$248.2m | -AU$39,797,313.00 | 21.5x | -11.9x | 1.9x |
| Fri, 08 Dec 2023 | AU$567.0m | AU$248.6m | -AU$52,451,569.00 | 19.4x | -10.8x | 2.3x |
| Sun, 05 Nov 2023 | AU$544.9m | AU$248.6m | -AU$52,451,569.00 | 22.5x | -10.4x | 2.2x |
| Tue, 03 Oct 2023 | AU$570.9m | AU$248.6m | -AU$52,451,569.00 | 22.5x | -10.9x | 2.3x |
| Thu, 31 Aug 2023 | AU$581.9m | AU$254.8m | -AU$41,743,595.00 | 22.5x | -13.9x | 2.3x |
| Sat, 29 Jul 2023 | AU$656.2m | AU$221.5m | -AU$37,611,177.00 | 25.2x | -17.4x | 3x |
| Mon, 26 Jun 2023 | AU$658.7m | AU$221.5m | -AU$37,611,177.00 | 24.6x | -17.5x | 3x |
| Wed, 24 May 2023 | AU$638.0m | AU$221.5m | -AU$37,611,177.00 | 28.7x | -17x | 2.9x |
| Fri, 21 Apr 2023 | AU$677.1m | AU$221.5m | -AU$37,611,177.00 | 28.3x | -18x | 3.1x |
| Sun, 19 Mar 2023 | AU$705.9m | AU$221.7m | -AU$39,169,534.00 | 29x | -18x | 3.2x |
| Tue, 14 Feb 2023 | AU$801.6m | AU$184.6m | -AU$29,264,632.00 | 34.8x | -27.4x | 4.3x |
| Thu, 12 Jan 2023 | AU$836.5m | AU$184.6m | -AU$29,264,632.00 | 35.1x | -28.6x | 4.5x |
| Sat, 10 Dec 2022 | AU$771.3m | AU$184.6m | -AU$29,264,632.00 | 32.1x | -26.4x | 4.2x |
| Mon, 07 Nov 2022 | AU$767.8m | AU$184.6m | -AU$29,264,632.00 | 29.6x | -26.2x | 4.2x |
| Wed, 05 Oct 2022 | AU$783.9m | AU$184.6m | -AU$29,264,632.00 | 33.1x | -26.8x | 4.2x |
| Fri, 02 Sep 2022 | AU$843.9m | AU$187.3m | -AU$29,669,583.00 | 34.2x | -28.4x | 4.5x |
| Sun, 31 Jul 2022 | AU$886.8m | AU$150.4m | -AU$31,222,532.00 | 28x | -28.4x | 5.9x |
| Tue, 28 Jun 2022 | AU$847.3m | AU$150.4m | -AU$31,222,532.00 | 27.6x | -27.1x | 5.6x |
| Thu, 26 May 2022 | AU$1.0b | AU$150.4m | -AU$31,222,532.00 | 31.4x | -32.7x | 6.8x |
| Sat, 23 Apr 2022 | AU$1.2b | AU$150.2m | -AU$30,481,316.00 | 25x | -39.5x | 8x |
| Mon, 21 Mar 2022 | AU$1.1b | AU$167.1m | -AU$90,069,489.00 | 23.3x | -12.6x | 6.8x |
| Wed, 16 Feb 2022 | AU$1.4b | AU$160.5m | -AU$82,212,457.00 | 67.3x | -17.4x | 8.9x |
| Fri, 14 Jan 2022 | AU$1.7b | AU$138.2m | -AU$84,243,063.00 | 142.6x | -19.8x | 12.1x |
| Sun, 12 Dec 2021 | AU$1.3b | AU$138.2m | -AU$84,243,063.00 | 102.7x | -15.9x | 9.7x |
| Tue, 09 Nov 2021 | AU$1.4b | AU$138.2m | -AU$84,243,063.00 | 108x | -16.7x | 10.2x |
| Thu, 07 Oct 2021 | AU$1.4b | AU$138.2m | -AU$84,243,063.00 | 113.7x | -16.3x | 9.9x |
| Sat, 04 Sep 2021 | AU$1.4b | AU$148.9m | -AU$96,965,525.00 | 92.7x | -14.6x | 9.5x |
| Mon, 02 Aug 2021 | AU$1.5b | AU$148.9m | -AU$96,965,525.00 | 87.2x | -15.3x | 9.9x |
Price to Earnings Ratio
-15.3x
Current Industry PE
- Investors are pessimistic on the Australian Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 5.0x is higher than the industry's current PS ratio of 2.6x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have improved over the last three years.
- Revenues for these companies have grown 18% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Comparison
How does Australian Clinical Research and Equipment compare with similar industries?
| AU Market | -2.20% | |
| Healthcare | -1.08% | |
| Life Sciences | -3.44% | |
| Clinical Research and Equipment | -3.44% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| TRJ Trajan Group Holdings | AU$1.04 | 5.9% +AU$8.8m | -43.9% | PS1x | |
| PIQ Proteomics International Laboratories | AU$0.91 | 3.4% +AU$3.9m | 13.8% | PS39.3x | |
| MEM Memphasys | AU$0.008 | 14.3% +AU$1.4m | -50.0% | PS15x |